Literature DB >> 19129747

Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus.

Y Okada1, K Nakamura, K Hiromura, Y Nojima, R Horiuchi, K Yamamoto.   

Abstract

We evaluated the relationship between the efficacy of low-dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase (ITPA) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). We performed a multiple regression analysis to assess the influence of various factors on the reduction in SLE disease activity index (SLEDAI) scores. The ITPA 94C>A polymorphism had the highest correlation with the change in SLEDAI score (r = 0.354, P = 0.006).

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19129747     DOI： 10.1038/clpt.2008.261

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Modulation of mutagenesis in eukaryotes by DNA replication fork dynamics and quality of nucleotide pools.

Authors:  Irina S-R Waisertreiger; Victoria G Liston; Miriam R Menezes; Hyun-Min Kim; Kirill S Lobachev; Elena I Stepchenkova; Tahir H Tahirov; Igor B Rogozin; Youri I Pavlov
Journal:  Environ Mol Mutagen       Date:  2012-10-10       Impact factor: 3.216

2.  The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic core.

Authors:  Peter D Simone; Lucas R Struble; Admir Kellezi; Carrie A Brown; Corinn E Grabow; Irine Khutsishvili; Luis A Marky; Youri I Pavlov; Gloria E O Borgstahl
Journal:  J Struct Biol       Date:  2013-03-23       Impact factor: 2.867

3.  Quantitative in vitro and in vivo characterization of the human P32T mutant ITPase.

Authors:  Greg Herting; Katie Barber; Maria R Zappala; Richard P Cunningham; Nicholas E Burgis
Journal:  Biochim Biophys Acta       Date:  2009-11-13

Review 4.  Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?

Authors:  Gabriele Stocco; Marco Pelin; Raffaella Franca; Sara De Iudicibus; Eva Cuzzoni; Diego Favretto; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

5.  Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease.

Authors:  Rihwa Choi; Mi-Na Lee; Kyunga Kim; Sun-Young Baek; Tae Jun Kim; Sung Noh Hong; Young-Ho Kim; Soo-Youn Lee
Journal:  Br J Clin Pharmacol       Date:  2020-06-01       Impact factor: 4.335

Review 6.  A disease spectrum for ITPA variation: advances in biochemical and clinical research.

Authors:  Nicholas E Burgis
Journal:  J Biomed Sci       Date:  2016-10-22       Impact factor: 8.410

7.  Measuring deaminated nucleotide surveillance enzyme ITPA activity with an ATP-releasing nucleotide chimera.

Authors:  Debin Ji; Elena I Stepchenkova; Jian Cui; Miriam R Menezes; Youri I Pavlov; Eric T Kool
Journal:  Nucleic Acids Res       Date:  2017-11-16       Impact factor: 16.971

8.  Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study.

Authors:  Zhao-Yang Chen; Yang-Hui Zhu; Ling-Yan Zhou; Wei-Qiao Shi; Zhou Qin; Bin Wu; Yu Yan; Yu-Wen Pei; Ning-Ning Chao; Rui Zhang; Mi-Ye Wang; Ze-Hao Su; Xiao-Jun Lu; Zhi-Yao He; Ting Xu
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

Review 9.  Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.

Authors:  Hong-Li Guo; Yue-Tao Zhao; Wei-Jun Wang; Na Dong; Ya-Hui Hu; Yuan-Yuan Zhang; Feng Chen; Li Zhou; Tao Li
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

10.  Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.

Authors:  Gabriele Stocco; Raffaella Franca; Federico Verzegnassi; Margherita Londero; Marco Rabusin; Giuliana Decorti
Journal:  Front Genet       Date:  2013-01-07       Impact factor: 4.599
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.